Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 164913, 8 pages
http://dx.doi.org/10.1155/2015/164913
Review Article

Association between HMGB1 and COPD: A Systematic Review

1School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University Hospital “G. Martino”, University of Messina, 98125 Messina, Italy
2Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy
3Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, University Pole Annunziata, 98168 Messina, Italy
4Institute of Applied Sciences and Intelligent Systems (ISASI), Messina Unit, 98100 Messina, Italy

Received 2 September 2015; Revised 12 November 2015; Accepted 3 December 2015

Academic Editor: Tânia Silvia Fröde

Copyright © 2015 Sebastiano Gangemi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. H. Goodwin and E. W. Johns, “Are the high mobility group non-histone chromosomal proteins associated with ‘active’ chromatin?” Biochimica et Biophysica Acta, vol. 519, no. 1, pp. 279–284, 1978. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Landsman and M. Bustin, “A signature for the HMG-1 box DNA-binding proteins,” BioEssays, vol. 15, no. 8, pp. 539–546, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. H. W. Chung, J.-B. Lim, S. Jang, K. J. Lee, K. H. Park, and S. Y. Song, “Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma,” Cancer Science, vol. 103, no. 9, pp. 1714–1721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Romani, T. C. Rodman, G. Vidali, and M. Bustin, “Serological analysis of species specificity in the high mobility group chromosomal proteins,” The Journal of Biological Chemistry, vol. 254, no. 8, pp. 2918–2922, 1979. View at Google Scholar · View at Scopus
  5. M. E. Bianchi and A. Agresti, “HMG proteins: dynamic players in gene regulation and differentiation,” Current Opinion in Genetics and Development, vol. 15, no. 5, pp. 496–506, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Hock, T. Furusawa, T. Ueda, and M. Bustin, “HMG chromosomal proteins in development and disease,” Trends in Cell Biology, vol. 17, no. 2, pp. 72–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Samy and L. H. Lim, “DAMPs and influenza virus infection in ageing,” Ageing Research Reviews, vol. 24, pp. 83–97, 2015. View at Publisher · View at Google Scholar
  8. S. D. Pouwels, M. C. Nawijn, E. Bathoorn et al., “Increased serum levels of LL37, HMGB1 and S100A9 during exacerbation in COPD patients,” European Respiratory Journal, vol. 45, no. 5, pp. 1482–1485, 2015. View at Publisher · View at Google Scholar
  9. R. Kang, R. Chen, Q. Zhang et al., “HMGB1 in health and disease,” Molecular Aspects of Medicine, vol. 40, pp. 1–116, 2014. View at Publisher · View at Google Scholar
  10. D. Tang, T. R. Billiar, and M. T. Lotze, “A Janus tale of two active high mobility group box 1 (HMGB1) redox states,” Molecular Medicine, vol. 18, no. 10, pp. 1360–1362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. GOLD, “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” 2015, http://www.goldcopd.org/.
  12. V. Kim, T. J. Rogers, and G. J. Criner, “New concepts in the pathobiology of chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 5, no. 4, pp. 478–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” PLoS Medicine, vol. 6, no. 7, Article ID e1000100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G.-H. Shang, C.-Q. Jia, H. Tian et al., “Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer,” Respiratory Medicine, vol. 103, no. 12, pp. 1949–1953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ferhani, S. Letuve, A. Kozhich et al., “Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 9, pp. 917–927, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Hou, H. Zhao, L. Liu et al., “High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls,” Molecular Medicine, vol. 17, no. 7-8, pp. 807–815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. F. S. Bezerra, S. S. Valença, K. M. P. Pires et al., “Long-term exposure to cigarette smoke impairs lung function and increases HMGB-1 expression in mice,” Respiratory Physiology and Neurobiology, vol. 177, no. 2, pp. 120–126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Kanazawa, Y. Tochino, K. Asai, Y. Ichimaru, T. Watanabe, and K. Hirata, “Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD,” European Journal of Clinical Investigation, vol. 42, no. 4, pp. 419–426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Wang, M. Jiang, and H. J. Wang, “Effect of NF-κB inhibitor on high-mobility group protein B1 expression in a COPD rat model,” Molecular Medicine Reports, vol. 7, no. 2, pp. 499–502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. H.-K. Ko, W.-H. Hsu, C.-C. Hsieh, T.-C. Lien, T.-S. Lee, and Y. R. Kou, “High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers,” Respirology, vol. 19, no. 2, pp. 253–261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Zhang, S. Li, G. Wang et al., “Changes of HMGB1 and sRAGE during the recovery of COPD exacerbation,” Journal of Thoracic Disease, vol. 6, no. 6, pp. 734–741, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Zabini, S. Crnkovic, H. Xu et al., “High-mobility group box-1 induces vascular remodelling processes via c-Jun activation,” Journal of Cellular and Molecular Medicine, vol. 19, no. 5, pp. 1151–1161, 2015. View at Google Scholar
  23. A. Di Stefano, G. Caramori, A. Barczyk et al., “Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD,” Thorax, vol. 69, no. 6, pp. 516–524, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Iwamoto, J. Gao, V. Pulkkinen, T. Toljamo, P. Nieminen, and W. Mazur, “Soluble receptor for advanced glycation end-products and progression of airway disease,” BMC Pulmonary Medicine, vol. 14, no. 1, article 68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. I. H. Heijink, S. D. Pouwels, C. Leijendekker et al., “Cigarette smoke-induced damage-associated molecular pattern release from necrotic neutrophils triggers proinflammatory mediator release,” American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 5, pp. 554–562, 2015. View at Publisher · View at Google Scholar
  26. I. E. Dumitriu, P. Baruah, A. A. Manfredi, M. E. Bianchi, and P. Rovere-Querini, “HMGB1: guiding immunity from within,” Trends in Immunology, vol. 26, no. 7, pp. 381–387, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Evans, T. W. J. Lennard, and B. R. Davies, “High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing?” Journal of Surgical Oncology, vol. 88, no. 2, pp. 86–99, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Palumbo, M. Sampaolesi, F. De Marchis et al., “Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation,” The Journal of Cell Biology, vol. 164, no. 3, pp. 441–449, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. H. J. Huttunen, C. Fages, and H. Rauvala, “Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways,” The Journal of Biological Chemistry, vol. 274, no. 28, pp. 19919–19924, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. S. P. Jong, F. Gamboni-Robertson, Q. He et al., “High mobility group box 1 protein interacts with multiple Toll-like receptors,” The American Journal of Physiology—Cell Physiology, vol. 290, no. 3, pp. C917–C924, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Sasahira, Y. Akama, K. Fujii, and H. Kuniyasu, “Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas,” Virchows Archiv, vol. 446, no. 4, pp. 411–415, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Takada, K. Hirata, T. Ajiki, Y. Suzuki, and Y. Kuroda, “Expression of Receptor for Advanced Glycation End products (RAGE) and MMP-9 in human pancreatic cancer cells,” Hepatogastroenterology, vol. 51, no. 58, pp. 928–930, 2004. View at Google Scholar · View at Scopus
  33. A. Taguchi, D. C. Blood, G. del Toro et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Degryse, T. Bonaldi, P. Scaffidi et al., “The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells,” Journal of Cell Biology, vol. 152, no. 6, pp. 1197–1206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. R. De Mori, S. Straino, A. Di Carlo et al., “Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2377–2383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Straino, A. Di Carlo, A. Mangoni et al., “High-mobility group box 1 protein in human and murine skin: involvement in wound healing,” Journal of Investigative Dermatology, vol. 128, no. 6, pp. 1545–1553, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. H. Youn, Y. J. Oh, E. S. Kim, J. E. Choi, and J.-S. Shin, “High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes,” Journal of Immunology, vol. 180, no. 7, pp. 5067–5074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Sha, J. Zmijewski, Z. Xu, and E. Abraham, “HMGB1 develops enhanced proinflammatory activity by binding to cytokines,” Journal of Immunology, vol. 180, no. 4, pp. 2531–2537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Bierhaus, P. M. Humpert, M. Morcos et al., “Understanding RAGE, the receptor for advanced glycation end products,” Journal of Molecular Medicine, vol. 83, no. 11, pp. 876–886, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Brett, A. M. Schmidt, S. D. Yan et al., “Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues,” The American Journal of Pathology, vol. 143, no. 6, pp. 1699–1712, 1993. View at Google Scholar · View at Scopus
  41. P. Morbini, C. Villa, I. Campo, M. Zorzetto, S. Inghilleri, and M. Luisetti, “The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?” Modern Pathology, vol. 19, no. 11, pp. 1437–1445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Ito, J. Fukazawa, and M. Yoshida, “Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils,” The Journal of Biological Chemistry, vol. 282, no. 22, pp. 16336–16344, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Rowe, P. L. Jackson, G. Liu et al., “Potential role of high-mobility group box 1 in cystic fibrosis airway disease,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 8, pp. 822–831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. O. O. Ojo, M. H. Ryu, A. Jha, H. Unruh, and A. J. Halayko, “High Mobility Group Box 1 (HMGB1) promotes extracellular matrix synthesis and wound repair in human bronchial epithelial cells,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 309, no. 11, pp. L1354–L1366, 2015. View at Publisher · View at Google Scholar
  45. E. Mortaz, I. M. Adcock, F. L. M. Ricciardolo et al., “Anti-inflammatory Eeffects of Lactobacillus rahmnosus and bifidobacterium breve on cigarette smoke activated human macrophages,” PLoS ONE, vol. 10, no. 8, Article ID e0136455, 2015. View at Publisher · View at Google Scholar